Adrenocortical Carcinoma - Epidemiology Forecast - 2034

Published Date : 2025
Pages : 60
Region : United States,

Share:

Adrenocortical Carcinoma Epidemiology

Adrenocortical Carcinoma (ACC)  Insights and Trends

  • According to DelveInsight’s analysis, the total incident cases of ACC were approximately 1,250 in the 7MM, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025. 

  • ACC is a rare but aggressive malignancy arising from the adrenal cortex. Its etiology remains largely elusive, although genetic mutations and hereditary syndromes are implicated. Risk factors encompass age, gender disparities, and specific genetic predispositions. 

  • The oncocytic variant accounts for approximately 10% of adrenal cortical tumors and is the most common subtype, followed by the myxoid and sarcomatoid variants, which are both exceedingly rare. According to the 2022 WHO classification, oncocytic ACC is defined by the presence of oncocytic tumor cells comprising more than 90% of the tumor mass.

  • ACC is a rare, aggressive cancer of the adrenal cortex, often producing excess hormones like cortisol, leading to syndromes like cushing’s. 

  • The ENSAT staging system is widely used to classify ACC and guide treatment decisions, with stages ranging from stage I to stage IV.

  • Diagnosis of ACC involves a combination of hormonal evaluation and advanced imaging techniques to assess tumor functionality, size, and spread, with definitive confirmation achieved through histopathological analysis after surgical resection. 

  • A critical unmet need in ACC lies in establishing dependable screening methods for early detection. The majority of cases are diagnosed at advanced stages, hindering treatment options and prognoses. The absence of reliable screening tools delays identification, worsening patient outcomes.

Adrenocortical Carcinoma (ACC)  Epidemiology Forecast in the 7MM

  • 2025 Incident Cases of Adrenocortical Carcinoma (ACC): 1,250

  • 2036 Projected Incident Cases of ACC: XXX

  • ACC Growth Rate (2026–2036): ~0.1%

DelveInsight's ‘Adrenocortical Carcinoma  Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the ACC, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period

2022–2036

Historical Year

2022–2025

Forecast Period

2026–2036

Base Year

2026

Geographies Covered

  • North America: The US;

  • Europe: Germany, France, Italy, Spain, and the UK;

  • Asia-Pacific: Japan

Adrenocortical Carcinoma (ACC)  Epidemiology CAGR

(Study period/Forecast period)

~0.1% (2026–2036)

Adrenocortical Carcinoma (ACC)  Epidemiology Segmentation Analysis

Patient Burden Assessment

  • Total Incident Cases of ACC

  • Stage-specific Incident Cases of ACC 

  • Gender-specific Incident Cases of ACC

  • Age-specific Incident Cases of ACC

Adrenocortical Carcinoma (ACC)  Understanding and Diagnosis Algorithm

Adrenocortical Carcinoma (ACC)  Overview

ACC is a rare and aggressive malignancy arising from the adrenal cortex. It can occur at any age but shows a bimodal distribution, affecting young children and adults in their 40s–50s. ACC may be functioning (hormone-secreting) or non-functioning. Functioning tumors often produce excess cortisol, androgens, or aldosterone, leading to clinical syndromes such as cushing’s syndrome or virilization. Due to its aggressive nature, ACC is frequently diagnosed at an advanced stage, contributing to poor prognosis and high recurrence rates.

Further details are provided in the report.

Adrenocortical Carcinoma (ACC)  Diagnosis

Diagnosis of ACC involves a combination of biochemical evaluation and imaging studies. Hormonal workup is essential to detect excess steroid production, including cortisol, DHEA-S, and aldosterone levels. Imaging techniques such as contrast-enhanced CT or MRI help assess tumor size, characteristics, and local invasion, while PET scans may assist in detecting metastases. Histopathological confirmation following surgical resection or biopsy remains the gold standard, with criteria such as the Weiss score used to distinguish malignant from benign adrenal tumors. Early and accurate diagnosis is critical for improving outcomes.

Further details are provided in the report.

Adrenocortical Carcinoma (ACC)  Epidemiology

Key Findings from Adrenocortical Carcinoma (ACC)  Epidemiological Analysis and Forecast 

  • In the 7MM, the distribution of ACC cases across stages reveals that Stage IV has the highest cases at ~35%, followed by Stage II, Stage III, and Stage I at lowest; ~10%. The predominance of Stage IV ACC cases in the 7MM may stem from delayed diagnosis, aggressive disease behavior, and limited screening methods, highlighting the urgent need for improved detection strategies.

  • The incidence of ACC is observed to be higher in females (~60%) compared to males, indicating a notable gender disparity in disease occurrence.

  • The United States accounted for the highest incident cases of ACC, representing approximately 30% of total cases in the 7MM in 2025.

  • The incidence of ACC increases with age, with the highest proportion observed in individuals aged >60 years, followed closely by those aged 40–60 years.

Scope of the Report

  • The report covers a segment of a descriptive overview of ACC, explaining its causes, signs and symptoms, and pathogenesis.

  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Adrenocortical Carcinoma (ACC)  Patient Population Forecast

Report Key Strengths

  • Epidemiology‑based (Epi‑based) Bottom‑up Forecasting

  • 11-year Forecast 

  • Patient Burden Trends (by geography)

FAQs

  • What are the disease risks, burdens, and unmet needs of ACC? What will be the growth opportunities across the 7MM concerning the patient population with ACC?

  • What is the historical and forecasted ACC patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

  • To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.

  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Tags:

    Related Reports

    report image delveinsight

    Adrenocortical Carcinoma - Market Insight, Epidemiology And Market Forecast - 2036

    report image delveinsight

    Adrenocortical Carcinoma - Pipeline Insight, 2026

    License Type

    Offer

    Request Sample

    View Pricing

    Customize Reports As Per Your Needs

    Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

    Have a Question?

    We are happy to assist you.

    Support Person
    DelveInsight
    DelveInsight
    SUBSCRIPTION
    Platform

    Register for free trial today and gain instant access to 7000+ market
    research reports

    Latest Press Release